Australia Contraceptive Devices Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia contraceptive devices market is shifting from low-cost, per-use barrier products towards higher-value, long-acting devices. Condoms still form the largest revenue pool, but subsidy and training programmes are moving growth to intrauterine devices, implants and rings.

Three forces are shaping demand: Medicare rebates that now cover the time of insertion and removal; a retail condom aisle that is becoming more premium, non-latex and women-led; and public concern over rising sexually transmitted infections, which keeps barrier methods relevant.

In October 2025, Organon announced that NuvaRing would join the PBS from 1 November 2025. In June 2026, the government confirmed AUD 25.6 million for eight long-acting contraception centres, and in October 2026 Eudaemon Technologies announced a further AUD 10 million raise for its hydrogel condom.

Key Market Trends and Insights

• Rebate reset: From 1 November 2025 the Medicare rebate for intrauterine device insertion rose from AUD 93.55 to AUD 215.95, and for implant insertion from AUD 41.50 to AUD 100.40.
• Bulk billing uptake: By June 2026 more than 55,000 long-acting contraception services had been bulk billed since the new rebates began, showing price was a real barrier for patients.
• Ring affordability: NuvaRing moved onto the PBS on 1 November 2025 at AUD 31.60 per script, and the co-payment fell to a AUD 25 cap from 1 January 2026.
• Infection pressure: In September 2026 national surveillance reported 94,184 chlamydia, 42,393 gonorrhoea and 5,986 syphilis diagnoses for 2025, sustaining the public health case for condoms.

Australia Contraceptive Devices Market Size and Forecast

The market is moving from commodity barrier products towards a blend of premium condoms and clinician-placed long-acting devices that carry subsidy support. Condoms lead on revenue, while vaginal rings advance fastest from a small base after their PBS listing. Clinics and sexual health services gain share as bulk billing and free insertion centres expand, and the 25 to 34 age group grows quickest. Queensland leads regional growth, with New South Wales the largest market. Policy support, product innovation and persistent infection concerns underpin a durable outlook.

Key Takeaways: Australia Contraceptive Devices Market

Subsidy Shifts Value Towards Long-Acting Devices

Revenue is on course to expand by about 72% across the decade, from AUD 330.00 million in 2025 to AUD 569.05 million in 2035 at a 5.6% CAGR. Higher rebates, free insertion centres and capped co-payments lower the cost of switching from per-use methods.

Rings and Clinic Channels Lead Growth

Condoms remain the largest segment, but vaginal rings grow at an estimated 10.2% CAGR and clinics and sexual health services at an estimated 7.6% CAGR through 2035. The 25 to 34 age group advances at an estimated 6.4% as long-acting uptake spreads.

Local Condom Innovation Is Attracting Capital

Eudaemon Technologies, based in Sydney, announced in October 2026 that it is raising further capital for a latex-free hydrogel condom, with commercial launch targeted for 2028. The project shows Australian research moving towards commercial barrier products.

• Completed an oversubscribed seed round of AUD 4.5 million
• Launched a further AUD 10 million round
• Holds 61 granted patents

Australia Contraceptive Devices Market Report Summary

Key Insight

Subsidised insertion, a capped ring co-payment and persistent infection concerns shape the outlook. Condoms lead on revenue, while long-acting and ring devices add the fastest growth from smaller bases.

Key Trends in the Australia Contraceptive Devices Market

The Australia contraceptive devices market is being reshaped by new condom technology, infection surveillance, rising permanent contraception and premium non-latex launches.

October 2026 - Eudaemon Technologies Raises Capital for Hydrogel Condom

• Eudaemon Technologies, an Australian clinical-stage medtech company, announced a further AUD 10 million raise in October 2026 for trials, approvals and scale-up.
• Its hydrogel condom is latex-free, about half water, and is made at an Annandale facility in Sydney, with commercial launch targeted for 2028.
• The company completed an oversubscribed AUD 4.5 million seed round and aims to supply condoms for the Brisbane 2032 Olympics.

September 2026 - National Surveillance Shows Sustained Infection Burden

• UNSW reported on 15 September 2026 that 2025 diagnoses reached 94,184 for chlamydia, 42,393 for gonorrhoea and 5,986 for syphilis.
• Experts named condoms and regular testing as trusted prevention measures for gonorrhoea.
• Persistent infection levels support steady barrier demand even as long-acting methods gain share.

July 2026 - Adelaide University Reports Sharp Rise in Vasectomies

• Adelaide University researchers reported on 20 July 2026 that vasectomies among men aged 18 to 44 rose by more than 60% over the study period.
• Claims reached 29,848 procedures a year, with increases in every state and territory.
• Lead researcher Dr Jack Janetzki linked the trend to cost-of-living pressure and a record-low fertility rate of about 1.48.

April 2026 - LifeStyles Healthcare Launches SKYN Supreme Feel

• LifeStyles Healthcare Australia launched SKYN Supreme Feel on 24 April 2026 as a premium non-latex condom.
• The polyisoprene product is thinner than existing non-latex options and targets people with latex sensitivities.
• It is available through major retailers across Australia.

Key Insight

Innovation and public health data now move together. New materials, premium non-latex launches and rising infection counts sustain barrier demand, while permanent methods gain interest from cost-conscious men.

Recent Market Developments in the Australia Contraceptive Devices Market

Recent developments, presented from the most recent, show subsidy and training programmes widening access to long-acting devices while retailers reposition condoms.

September 2026 - Moments Survey Shows Easing Stigma at the Condom Aisle

• The Moments Sexual Health Study, published on 17 September 2026, surveyed 1,111 Australian women aged 18 to 45.
• It found 75.2% used at least one tactic to avoid being seen buying condoms, and 29.9% never buy condoms themselves.
• Discomfort at purchase was 23.9%, which Moments read as improving attitudes, though the fieldwork provider differed from earlier waves.

June 2026 - Government Funds Eight Long-Acting Contraception Centres

• On 5 June 2026 the Department of Health confirmed AUD 25.6 million for eight centres, one in each state and territory.
• The centres offer free advice and no-cost insertion and removal of intrauterine devices and implants, plus outreach training for regional clinicians.
• Primary Health Networks were to appoint providers by 1 July 2026.

January 2026 - PBS Co-Payment Cap Lowers Ring Costs

• From 1 January 2026 the maximum PBS charge for NuvaRing and other listed contraceptives fell to AUD 25 per script.
• Before its November 2025 listing, women could pay more than AUD 270 a year for the ring.
• A three-ring pack lasts three months, so the cap sets a clear annual price ceiling.

November 2025 - Medicare Rebates for Insertion and Removal Rise Sharply

• From 1 November 2025 the intrauterine device insertion rebate rose to AUD 215.95 and the implant insertion rebate to AUD 100.40.
• The government expects about 300,000 women a year to save up to AUD 400 in out-of-pocket costs.
• Free AusLARC training for clinicians, with travel scholarships, supports supply of insertion capacity.

Key Insight

Recent events widen access more than they change products. Higher rebates, free insertion centres and capped co-payments lower cost barriers, while retailers and researchers address stigma and consumer preferences.

Australia Contraceptive Devices Industry Segmentation

The Expert Market Research’s report on the Australia Contraceptive Devices Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Product Type

• Condoms
• Intrauterine Devices and Systems
• Contraceptive Implants
• Vaginal Rings
• Sterilisation Devices
• Others

Condoms lead revenue, with LifeStyles Healthcare launching SKYN Supreme Feel in April 2026 and Moments reporting steady retail demand. Intrauterine Devices and Systems grew after the November 2025 rebate rise to AUD 215.95 for insertion. Contraceptive Implants benefit from the AUD 100.40 insertion rebate. Vaginal Rings grow fastest at an estimated 10.2% CAGR after NuvaRing joined the PBS on 1 November 2025. Sterilisation Devices follow vasectomy demand, which Adelaide University reported rising in July 2026. Others covers female condoms, diaphragms and caps.

Market Breakup by Distribution Channel

• Retail Pharmacies
• Supermarkets and Convenience Stores
• Clinics and Sexual Health Services
• Online and Direct Sales
• Others

Retail Pharmacies lead, since Moments gained a place in Chemist Warehouse and ring prescriptions are dispensed there under the January 2026 PBS cap. Supermarkets and Convenience Stores carry mass-market condoms, with Coles stocking Moments. Clinics and Sexual Health Services grow fastest at an estimated 7.6% CAGR, helped by more than 55,000 bulk billed long-acting services by June 2026 and the eight centres announced on 5 June 2026. Online and Direct Sales suit private purchases, and Amazon lists Moments. Others covers public health and community distribution.

Market Breakup by User Age Group

• Under 25 Years
• 25 to 34 Years
• 35 to 44 Years
• 45 Years and Over
• Others

Under 25 Years is the heaviest condom group, since infection prevention matters alongside pregnancy prevention, and it grows at an estimated 4.9% CAGR. 25 to 34 Years grows fastest at an estimated 6.4%, as women in this group respond to cheaper insertion and the 1,111-woman Moments survey, published in September 2026, covered women up to 45. 35 to 44 Years leads on permanent methods, with Adelaide University reporting vasectomy growth among men aged 18 to 44, and grows at 5.9%. 45 Years and Over advances at 4.7%, driven by perimenopause care.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Others

New South Wales dominates through the largest population, growing at an estimated 5.4% CAGR, and hosts Eudaemon Technologies in Sydney. Victoria follows at 5.5%, with Western Victoria PHN named for its long-acting centre in June 2026. Queensland grows fastest at an estimated 6.1%, ahead of Western Australia at 5.9%, where WA Primary Health Alliance was named. South Australia grows at 5.3%, supported by SA Rural Health Network. Others covers Tasmania, the ACT and the Northern Territory at 5.7%; in Tasmania, over 13,000 women filled more than 34,000 newly subsidised prescriptions between March and September 2025.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Contraceptive Devices Market

Competition combines global pharmaceutical suppliers of clinician-placed devices with condom brands, local innovators and retailers. Entry barriers include TGA inclusion, clinician training, pharmacy and supermarket listings and brand trust.

Organon

Organon, headquartered in Jersey City, New Jersey, supplies women's health products in Australia through Organon ANZ in Sydney, including the NuvaRing vaginal ring and the Implanon NXT contraceptive implant. On 27 October 2025 it announced that NuvaRing would be PBS-listed from 1 November 2025 at AUD 31.60 per script, falling to a AUD 25 cap from 1 January 2026. Managing Director Bilal Somra called the listing a demonstration of government commitment to women's health.

Bayer

Bayer, headquartered in Leverkusen, Germany, operates through Bayer Australia and supplies hormonal intrauterine systems, including Mirena, Kyleena and Jaydess. Its devices are directly affected by the Medicare changes from 1 November 2025, which lifted the intrauterine device insertion rebate to AUD 215.95, and by the eight long-acting contraception centres confirmed on 5 June 2026. Its Australian arm is the sponsor of record for these devices on the TGA register.

LifeStyles Healthcare

LifeStyles Healthcare, headquartered in Singapore, markets the SKYN and LifeStyles condom brands in Australia through LifeStyles Healthcare Australia. On 24 April 2026 it launched SKYN Supreme Feel, a polyisoprene non-latex condom that is thinner than earlier non-latex options and aimed at people with latex sensitivities. The product is available through major retailers across Australia and extends the company's premium sexual wellness range.

Moments

Moments is an Australian sexual wellness brand launched under Coral Healthcare and led by founder and managing director Nikhil Daftary. It sells 15 condom varieties, five intimacy products and two lubricants, and is stocked at Coles, Chemist Warehouse and Amazon. On 17 September 2026 it published its Sexual Health Study of 1,111 women, finding 29.9% never buy condoms themselves, and it promotes a women-first approach to the condom aisle.

Other players operating in the Australia contraceptive devices market include Eudaemon Technologies, Reckitt, Karex, Glyde Health, and Okamoto Industries, alongside pharmacy chains, supermarkets, sexual health clinics and family planning services supporting condom, intrauterine device, implant and ring supply across Australia.

Key Insight

Competition rests on clinician access, product feel, retail placement and brand trust rather than price. Global suppliers hold the long-acting base, while local brands compete through design and shopper experience.